News/ Blog – Page 2 – Waldenstrom's Macroglobulinemia Foundation of Canada

Video: Dr. Dimopoulos Reflects on Ibrutinib Plus Rituximab in Waldenstrom Macroglobulinemia

Source: https://www.onclive.com/onclive-tv/dr-dimopoulos-reflects-on-ibrutinib-plus-rituximab-in-waldenstrom-macroglobulinemia

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients… Continue reading →

Article: Shingrix vaccine makes shingles less severe, disruptive to quality of life

Lisa Rapaport

4 MIN READ

(Reuters Health) – The vaccine Shingrix prevents shingles, and if people do contract the virus, it reduces the severity of illness, two company-funded study suggests.

Shingles, also known as herpes zoster, typically develops in older… Continue reading →

Article: Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients with Waldenstrom Macroglobulinemia

Abstract:

Purpose
Ibrutinib is active in previously treated Waldenstro¨m macroglobulinemia (WM). MYD88 mutations
(MYD88MUT) and CXCR4 mutations (CXCR4MUT) affect ibrutinib response. We report on a prospective
study of ibrutinib monotherapy in symptomatic, untreated patients with WM, and the effect
of… Continue reading →

Article: Selecting Initial Therapy for Newly Diagnosed Waldenstrom Macroglobulinemia

Article Abstract:

In the article that accompanies this editorial, Treon and colleagues
1 report on 30 newly diagnosed patients with Waldenstr¨om
macroglobulinemia (WM) treated with ibrutinib. Clinically relevant
responses were seen in all patients. Responses occurred rapidly
with an 18-month… Continue reading →

Article: Ibrutinib Monotherapy Effective in CXCR4- and MYD88- Mutated Waldenstrom Macroglobulinemia

Source: Cancer Therapy Advisor

Ibrutinib monotherapy is a highly active and tolerable option for treatment-naïve patients with Waldenström macroglobulinemia (WM), but may be affected by CXCR4-mutation status, according to a study published in the Journal of Clinical Oncology… Continue reading →

Cure Magazine covers WM

Cure Magazine’s special issue on Rare Cancers, published on August 1, 2018, includes an article entitled “Waldenstrom Macroglobulinemia: The Discovery and What Lies Ahead”.

The article goes on to describe WM, its rarity, and recent advances in treatment options for… Continue reading →

Video: Peter DeNardis – Patient Perspective on being newly diagnosed

Source: https://www.iwmf.com/library/media-library/peter-denardis-presentations

Recently, Dr. John Chapin, a Professor of Communications at the Pennsylvania State University’s Beaver Campus approached the IWMF about a project whereby his students would develop and produce short videos for the IWMF.

The end result is… Continue reading →

Article: Ibrutinib/Rituximab Emerges as New Standard in Waldenstrom Macroglobulinemia

Meletios A. Dimopoulos, MD

Results from the phase III iNNOVATE (PCYC-1127) trial established the combination of ibrutinib (Imbruvica) plus rituximab (Rituxan) as the new standard of care in Waldenström macroglobulinemia, said Meletios A. Dimopoulos, MD.

Dimopoulos, professor and chairman… Continue reading →

Article: Exploring Use of Ibrutinib/Rituximab Combination for Waldenström Macroglobulinemia

JULY 06, 2018

Kristi Rosa

Source: Rare Disease Report – https://www.raredr.com/conferences/asco2018/exploring-use-of-ibrutinib-rituximab-combination-for-waldenstrom-macroglobulinemia

A type of non-Hodgkin lymphoma, Waldenström macroglobulinemia is a rare, slow-growing lymphoproliferative disorder that is estimated to affect only 1,000 to 1,500 individuals each year in the… Continue reading →

Book Recommendations

We are compiling a reading list of books that our members have recommended. Please feel free to send us titles that you have found inspiring and resourceful.

HAVE YOU READ……

“Things I wish I’d Known – Cancer Caregivers… Continue reading →